Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Real Estate
  • Business
  • Technology
  • Health
  • Artificial Intelligence
ncarol.com

Investor Workshop at Mar-A-Lago, $27 Million for Acquisitions and Drug Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. (Stock S: NRXP)
ncarol.com/10283061

Trending...
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand - 102
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position - 101
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
NASDAQ: NRXP $31 Target issued Nasdaq Nrxp NRXP 2 NRXP Chief Business Officer Nrxp 5 Corporate Ads
$NRXP $31 Price Target from Respected Investment Analyst D. Boral Capital

MIAMI - ncarol.com -- Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.

Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression

Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).

Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations

Kadima Neuropsychiatry Institute Targeted as First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics.

Completion of NDA Filing Expected in First Quarter of 2025


NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100.

More on ncarol.com
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West

In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link:

https://www.nrxpharma.com/wp-content/uploads/2025/01/HOPE-Therapeutics-Advances-With-Kadima.pdf.

Investor Workshop at the Mar-A-Lago Club

On January 10th NRXP announced it conducted an investor workshop to support planned expansion of subsidiary HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL.

The event was attended by Qualified Institutional Buyers as defined by the Securities and Exchange Commission and included Jonathan Javitt, MD, MPH, Chairman and CEO of NRXP together with Dallas Sauer, Founder of Smith and Sauer, the private investment firm that recently committed to invest in both NRXP and HOPE.

Key areas of investor discussions included:

NRXP HOPE's mission to build an international network of best-in class, EBITDA positive, interventional psychiatry clinics

$25 million financing committed by Smith and Sauer (JGS Holdings LLC) to leverage anticipated bank financing projected to secure $100 million in HOPE clinic revenue stream on a pro-forma basis

Recently announced progress for NRXP HOPE's initial clinic acquisitions

Potential mechanisms for follow-on non-dilutive financing to expand NRXP HOPE's network by an additional 50 clinics in 2026 and 100 clinics in 2027

NRXP has been invited to return to Mar-A-Lago for an expanded meeting during the last week of January that will include both Qualified Institutional Buyers and Accredited Investors.

Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations

On January 6th NRXP announced signing of a Binding Term Sheet with Smith & Sauer, LLC, for $25 million equity purchases to fund planned HOPE clinic subsidiary acquisitions. Company management anticipates this new capital in combination with anticipated bank and/or bond lending, to be sufficient to drive substantial revenue in HOPE clinic acquisition during 2025. An additional $2 million equity investment in NRXP will be used to advance the Company's new drug applications for NRX-100 and NRX-101.

Benefits of this agreement include:

More on ncarol.com
  • The Seaside Art Gallery Presents
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
  • Asheville-Based KayeDinero Surpasses 100-Track Goal as Detroit Lions Win 35-10 in Munich
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • Nious Media Expands Gaming Coverage With 2026 Game & Geek Expo Special

Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRXP operations.

Purchase of $25 million in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions.

Purchase $2 million in NRXP equity, above the most recent closing price, at $2.75 per share. Investor will also purchase 500,000 NRXP shares from existing shareholders for $2.75 per share

In connection with both investments, investor shall receive warrants to purchase 3 million currently unregistered shares of NRXP common stock at $3.00 per share with a 24-month term.

Smith & Sauer will also be entitled to receive royalties on net revenues from NRXP product sales to a defined rate of return

Investment in HOPE Therapeutics is expected to enhance the NRXP balance sheet value, strengthening its financial position.

Smith & Sauer to join the HOPE Therapeutics and NRx Pharmaceuticals' Boards of Directors

Kadima Neuropsychiatry Institute Expected First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics

On January 2nd NRXP announced the planned acquisition of the Kadima Neuropsychiatry Institute of La Jolla, CA, per the previously announced Letter of Intent, for the Company's HOPE subsidiary network. Kadima is expected to serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and PTSD.

Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

On December 30th NRXP announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the U.S. Food & Drug Administration (FDA). NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for treatment of suicidal bipolar depression.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
Corporate Ads
***@gmail.com


Source: Corporate Ads
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
  • CB Stuffer Announces Private Sale to Secure Future of Brand Growth
  • The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
  • Apex Wellness Architect Hosts Intimate Tea & Intentions Tea Bar Experience to Close Out the Year
  • Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
  • Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Lake Norman Philharmonic Annual Holiday Concert 2026
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
  • Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
  • New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
  • Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
  • Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
  • The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
_catLbl0 _catLbl1

Popular on ncarol.com

  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 214
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 195
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform - 194
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 135
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs - 124
  • 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST) - 123
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 120
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA) - 115
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers - 113
  • KayeDinero Drops "CyberLeek" Amid GTA VI Headlines, Unveils Asheville "Barksdale" Visual - 111

Similar on ncarol.com

  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • After Nvidia's 14% Drop, Asheville Artist KayeDinero Releases "Nvidia"
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute